The nation of Zimbabwe has rejected a major American health deal valued at 367 million US dollars (£272m) spanning five years because of the United States' insistence on confidential biological samples.
This move became public after a official document from December was disclosed, indicating that President Emmerson Mnangagwa believed the arrangement was "skewed".
A government representative later clarified that the United States was demanding access to genetic material for research and commercial purposes while refused to guarantee the benefits from any future treatments.
"We are forced to start the challenging and unfortunate process of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged more dialogue to secure a agreement suitable to all parties so the nation's critical HIV treatment initiative can continue.
Wider Context
This development follows a comparable situation in neighbouring Kenya, where a high court halted a similar deal with the US after concerns were filed about the safety of Kenyans' medical information.
After returning to office recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump claimed its spending was "inefficient" and his government was seeking government-to-government deals to boost transparency and accountability.
According to reports, 16 African countries have to date agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving HIV treatment via American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Our nation was requested to share its biological resources and data for a long time, without any equivalent promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Effectively, our nation would provide the raw materials for scientific discovery without any assurance that the final treatments would be accessible to our citizens should a new pandemic emerge."
Sovereignty and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were undermining structures already established through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This mechanism is designed to guarantee that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome continued dialogue with our US partners on how subsequent co-operation might be designed in a manner that respects the independence and interests of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but urged that negotiations should continue since a large portion of the nation's Aids initiatives relied on international support.
"In cases where technical issues arise, such as those relating to data governance or implementation frameworks, these can often be addressed via detailed discussion and negotiated safeguards," it commented.
The situation underscores the complex challenges between receiving much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.